Gyre Therapeutics (GYRE) vs Olema Pharmaceuticals (OLMA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Gyre Therapeutics (GYRE) has outperformed Olema Pharmaceuticals (OLMA) over the past year, losing 7.4% versus a loss of 27.1%. Over five years, OLMA leads with a -74.1% price change compared with -88.7% for GYRE. Gyre Therapeutics is the larger company by market cap ($743.3 million vs $694.7 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GYRE | OLMA |
|---|---|---|
| Share price | $7.01 | $7.94 |
| Market cap | $743.30M | $694.73M |
| 1-day change | +3.70% | +1.53% |
| YTD return | -4.25% | -68.72% |
| 1-year return | -7.40% | -27.12% |
| 5-year return | -88.73% | -74.15% |
| Forward P/E | 116.83 | — |
| EPS (TTM) | $-0.25 | $-2.12 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $9.42 | $36.26 |
| 52-week low | $5.44 | $6.65 |
| Distance from 52-week high | -25.58% | -78.10% |
| Analyst consensus | none | none |
| Avg. price target upside | +166.33% | +359.70% |
| Average volume | 105.93K | 1.06M |
| Shares outstanding | 106.03M | 87.50M |
| Employees | 625 | 150 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- GYRE has outperformed OLMA by 19.7 percentage points over the past year.
About Gyre Therapeutics
GYRE stock →Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. The company offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under Phase 3 trials for the treatment of pneumoconiosis.
Health Care · Biotechnology: Pharmaceutical Preparations · 625 employees
About Olema Pharmaceuticals
OLMA stock →Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. The company's lead product candidate is palazestrant, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic ER-positive, human epidermal growth factor receptor 2-negative breast cancer; OPERA-01, the pivotal Phase 3 clinical trial of palazestrant as a monotherapy in second/third-line ER+/HER2- metastatic breast cancer; and palazestrant with CDK4/6 inhibitors, a phosphatidylinositol 3 kinase alpha (PI3Ka) inhibitor alpelisib, a mechanistic target of rapamycin inhibitor, and a CDK4 inhibitor that is in Phase 1b/2 clinical trial for the treatment of ER+/HER2- advanced or metastatic breast cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 150 employees
GYRE vs OLMA FAQ
Which is bigger, Gyre Therapeutics or Olema Pharmaceuticals?
Gyre Therapeutics (GYRE) is larger, with a market capitalization of $743.30M compared with $694.73M for Olema Pharmaceuticals (OLMA).
Which stock has performed better over the past year, GYRE or OLMA?
GYRE returned -7.40% over the past 12 months, compared with -27.12% for OLMA (price return, excluding dividends). Past performance does not predict future results.
Are Gyre Therapeutics and Olema Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.